According to Revance Therapeutics's latest financial reports the company's current revenue (TTM) is $0.23 B. In 2022 the company made a revenue of $0.13 B an increase over the years 2021 revenue that were of $77.79 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.23 B | 76.55% |
2022 | $0.13 B | 70.4% |
2021 | $77.79 M | 407.65% |
2020 | $15.32 M | 3610.65% |
2019 | $0.41 M | -88.92% |
2018 | $3.72 M | 1322.9% |
2017 | $0.26 M | -12.67% |
2016 | $0.3 M | 0% |
2015 | $0.3 M | -21.67% |
2014 | $0.38 M | -37.93% |
2013 | $0.61 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $93.02 B | 39,646.20% | ๐บ๐ธ USA |
Biogen BIIB | $9.66 B | 4,028.82% | ๐บ๐ธ USA |
MediciNova MNOV | $1 M | -99.57% | ๐บ๐ธ USA |